Janssen terminates daratumab development i... Genmab A/S has announced that its CD38-targeting Phase II candidate daratumab did not reach the expected ORR in non-Hodgkin’s lymphoma patients. Co-developer Janssen has decided to terminate development … more ➔
Biostep Forum: Bioeconomy strategy update...The evaluation of the European bioeconomy strategy will take longer than initially planned. According to information given at the Biostep Forum in Brussels, results won’t be available before next … more ➔
Selvita to cash in €90m in Menarini dealPolish drug developer Selvita has out-licenced its first lead compound to Berlin-Chemie Menarini, a company of the Menarini Group. Ongoing clinical trails with SEL 24 will be conducted … more ➔
EU nations go on blocking GM cropsThe EU’s opt-out clause for GM cultivation has missed its goal to accelerate EU market approval of safety-assessed genetically modified crops whilst giving member states the option to opt out from cultivation … more ➔
EMA backs three orphan drugsThree of six new meds to be approved in Europe are orphan drugs and have been backed by the European Medicines Agency (EMA) this month. more ➔
FDA approves Merck’s avelumab in MCC Good news for EMD Serono, the US arm of German Merck: It’s PD-L1 blocker avelumab is the first drug that received FDA approval to treat the rare skin cancer Merkel Cell Carcinoma (MCC). more ➔
BIO-Europe Spring: Southern growth ambitio...With around 2,500 attendees, Barcelona hosted the most successful BIO Europe Spring conference in the history of the EBD’s partnering event. Southern Europe demonstrated its growth ambitions in the life … more ➔
Toxoplasmosis: novel target to prevent tra... Scottish and Canadian researchers have identified a protein essential for the toxoplasmosis parasite to be transmitted. Targeting it might give rise to new treatments other parasitic diseases like … more ➔
Pulmocide raises £25m in Series B roundBritish inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing. more ➔
Investors purchase ImegenThe investment groups Q-Growth Fund and Biolty purchased the majority of the Valencian biotechnology company Institute of Genomic Medicine (Imegen) for €10m. more ➔
